Growth Metrics

BeOne Medicines (BEIGF) Return on Invested Capital (2016 - 2025)

BeOne Medicines (BEIGF) has disclosed Return on Invested Capital for 10 consecutive years, with 0.07% as the latest value for Q4 2025.

  • Quarterly Return on Invested Capital rose 25.0% to 0.07% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.07% through Dec 2025, up 25.0% year-over-year, with the annual reading at 0.07% for FY2025, 25.0% up from the prior year.
  • Return on Invested Capital for Q4 2025 was 0.07% at BeOne Medicines, up from 0.02% in the prior quarter.
  • The five-year high for Return on Invested Capital was 0.07% in Q4 2025, with the low at 0.4% in Q1 2023.
  • Average Return on Invested Capital over 5 years is 0.22%, with a median of 0.23% recorded in 2024.
  • The sharpest move saw Return on Invested Capital skyrocketed 33bps in 2021, then dropped -26bps in 2022.
  • Over 5 years, Return on Invested Capital stood at 0.13% in 2021, then tumbled by -199bps to 0.39% in 2022, then grew by 20bps to 0.31% in 2023, then surged by 42bps to 0.18% in 2024, then skyrocketed by 137bps to 0.07% in 2025.
  • According to Business Quant data, Return on Invested Capital over the past three periods came in at 0.07%, 0.02%, and 0.06% for Q4 2025, Q3 2025, and Q2 2025 respectively.